Mereo BioPharma (MREO) Cash from Investing Activities (2023 - 2026)
Mereo BioPharma (MREO) posted quarterly Cash from Investing Activities of -$300000.0 for Q1 2026, up 6.25% year-on-year from -$282352.9 in Q1 2025, and down 200.0% on a QoQ basis from $300000.0 in Q3 2025.
Mereo BioPharma (MREO) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Cash from Investing Activities for 4 consecutive years, with -$300000.0 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Investing Activities rose 6.25% year-over-year to -$300000.0 in Q1 2026, while the trailing twelve-month figure through Dec 2025 was -$20000.0 (up 97.14% YoY) and the FY2025 annual result came in at -$20000.0, up 97.14% from the prior year.
- Cash from Investing Activities declined to -$300000.0 in Q1 2026 per MREO's latest filing, from $300000.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for MREO reached as high as $300000.0 in Q3 2025 and fell as low as -$700000.0 in Q1 2024.
- A 4-year average of -$239666.7 and a median of -$310000.0 in 2025 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities plunged 67.06% — and 2025, when it jumped 54.29%.
- Year by year, Cash from Investing Activities stood at -$419000.0 in 2023, then soared by 100.24% to $1000.0 in 2024, then soared by 29900.0% to $300000.0 in 2025, then tumbled by 200.0% to -$300000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$300000.0, $300000.0, and -$320000.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Mereo BioPharma | 242.07 Mn | 242.07 Mn | - | -300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -300,000.00 |
| Mar 31, 2026 | -300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Mar 31, 2025 | -320,000.00 |
| Mar 31, 2025 | -320,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | -700,000.00 |
| Mar 31, 2024 | -700,000.00 |
| Mar 31, 2023 | -419,000.00 |
| Mar 31, 2023 | -419,000.00 |